Migraine is a common episodic neurological disorder, typically presenting with recurrent attacks of severe headache and autonomic dysfunction. Apart from rare monogenic subtypes, no genetic or molecular markers for migraine have been convincingly established. We identified the minor allele of rs1835740 on chromosome 8q22.1 to be associated with migraine (P = 5.38 × 10 −9 , odds ratio = 1.23, 95% CI 1.150-1.324) in a genome-wide association study of 2,731 migraine cases ascertained from three European headache clinics and 10,747 population-matched controls. The association was replicated in 3,202 cases and 40,062 controls for an overall meta-analysis P value of 1.69 × 10 −11 (odds ratio = 1.18, 95% CI 1.127-1.244). rs1835740 is located between MTDH (astrocyte elevated gene 1, also known as AEG-1) and PGCP (encoding plasma glutamate carboxypeptidase). In an expression quantitative trait study in lymphoblastoid cell lines, transcript levels of the MTDH were found to have a significant correlation to rs1835740 (P = 3.96 × 10 −5 , permuted threshold for genome-wide significance 7.7 × 10 −5 ). To our knowledge, our data establish rs1835740 as the first genetic risk factor for migraine.
l e t t e r s depolarization [8] [9] [10] . However, these are considered to be downstream events, and it is unknown how migraine attacks are initiated.
To identify variants associated with the common forms of migraine, we carried out a two-stage GWAS in seven European migraine case collections (six clinic-based and one populationbased) (Supplementary Fig. 1 ). In the discovery stage, we studied 3,279 migraineurs (1,124 Finnish, 1,276 German and 879 Dutch individuals) recruited from headache clinics and genotyped using Illumina arrays against population-matched controls (10,747 individuals) recruited from preexisting population-based GWAS (Supplementary Note). In the replication stage, a further 3,202 cases and 40,062 population-matched controls from Iceland, Denmark, The Netherlands and Germany were studied.
Diagnoses were made by headache experts using a combination of questionnaires and individual interviews that were based on the ICHD-II guidelines 7 . Due to the overlap between individuals having migraine with aura and those having migraine without aura, we analyzed the following diagnostic subgroups: (i) 'all migraine' , defined as all individuals with migraine irrespective of subtype; (ii) 'migraine with aura only' , defined as individuals who only have attacks where aura is present; (iii) 'both migraine with aura and migraine without aura' , defined as individuals with attacks both with and without aura; and (iv) 'migraine without aura only' , defined as individuals with only attacks of migraine without aura.
We used a multipopulation CochranMantel-Haenszel (CMH) association analysis and a significance threshold of P ≤ 5 × 10 −8 in our analyses. In the discovery sample, 2,731 cases and 10,747 controls ( Table 1) passed quality control steps, and 429,912 markers were successfully genotyped (Online Methods). A quantile-quantile plot of the CMH analysis (Supplementary Fig. 2 ) and an overall inflation factor (λ) of 1.08 were used as final quality control measures.
Only one marker, rs1835740 on chromosome 8q22.1, showed significant association with migraine in the multipopulation CMH analysis ( Fig. 1 and Supplementary Fig. 3 ). Eleven further loci were found with P ≤ 5 × 10 −5 (Supplementary Table 1 ). The minor allele (A) of marker rs1835740 was associated with migraine with P = 5.38 × 10 −9 and odds ratios ranging between 1.21 and 1.33 ( Table 2) . Two nearby markers with the highest linkage disequilibrium (LD) to rs1835740 (rs982502, r 2 = 0.59, P = 1.34 × 10 −4 and rs2436046, r 2 = 0.69, P = 1.78 × 10 −5 ) also showed association with migraine (Supplementary Table 2) . Haplotype analysis detected a 27-kb haplotype (P = 5.35 × 10 −8 ) ( Supplementary Fig. 4 and Supplementary Table 3 ). In the HapMap Phase II data 11 , the variant is located between two close recombination hotspots, and analysis using the ssSNPer program 12 demonstrated that no long-range LD to rs1835740 exists within a 5-Mb window, strongly suggesting that the causative variant in this region is tagged by the minor allele of rs1835740 (Fig. 1) . The 2-Mb window around rs1835740 was also imputed against the 1000 Genomes data (August 2009 release), but no other marker showed evidence of association exceeding that for rs1835740 (Fig. 1) . Conditional analysis of the SNPs around rs1835740 showed no additional independent signals (Supplementary Table 2 ). The proportion of genetic variance explained by the rs1835740 variant was estimated to be between The blue graph shows the local recombination rate based on HapMap Phase II data 11 . The red line denotes the threshold for genome-wide significance (P ≤ 5 × 10 −8 ). This figure was generated using a modified version of the script available at http://www.broadinstitute.org/node/555. l e t t e r s 1.5% and 2.5%, depending on the heritability estimate used, and the population attributable risk was estimated to be 10.7% using previous methodology 13 . To confirm and extend our results, we performed a replication study on the only marker with genome-wide significance in the discovery stage: rs1835740. The diagnostic subgroups used in the discovery stage were also applied to the replication stage. Replication was successful in two 'migraine with aura only' subsets (Danish, P = 0.015, OR = 1.29 and Icelandic, P = 0.038, OR = 1.36), in the Icelandic 'migraine without aura' set (P = 0.0292, OR = 1.18) and in the Icelandic 'all migraine' group (P = 0.010, OR = 1.18) ( Table 2) . Overall, the A allele of marker rs1835740 was overrepresented (OR = 1.05-1.36; Table 2 ) in each subset of all replication samples except in the Danish 'both migraine with aura and migraine without aura' group (OR = 0.99). The effect was consistently stronger in the 'migraine with aura only' groups than other migraine subgroups (Fig. 2) . It should be noted that the majority of the groups that did not reach formal replication were small and had limited power. Meta-analysis was conducted using the CMH test for each diagnosis subgroup alone as well as for all migraine samples together, with the latter group showing a final P = 1.69 × 10 −11 ( Table 2) .
Marker rs1835740 is located between two potentially interesting candidate genes, MTDH and PGCP. We analyzed the effect of this marker's genotype on the expression of genes within a 2-Mb window in fibroblasts, primary T cells and lymphoblastoid cell lines (LCL) obtained from umbilical cords 14 . In the expression quantitative trait locus (eQTL) analysis, the rs1835740 genotype was found to have significant correlation a Values in this row were calculated after excluding an outlier control sample. The German replication control set consisted of several small samples. The largest of these had a considerably deviating minor allele frequency (MAF) (MAF = 0.238, n = 865) compared to other German (average MAF = 0.216, n = 3,260) and Central European control sets (average MAF = 0.212, n = 9,560).
Thus, values with both including and excluding the outlier control sample are presented in the case allele and control allele columns. The meta-analysis value includes all control samples (without the outlier control group, "all migraine without aura samples," P = 0.00107, OR = 1.18, 95% CI 1.068-1.298 and "all migraine samples," P = 8. Figure 2 For each dataset, the horizontal line indicates the 95% CI, and the number above the line indicates the point estimate of the odds ratio. MA only, individuals whose attacks are always accompanied with aura; both MA, MO, individuals with attacks with and without aura; MO only, individuals whose attacks never include aura.
l e t t e r s
to the transcript levels of the nearby MTDH gene in LCLs (Table 3 and  Supplementary Table 4) , with the risk allele A being associated with higher expression levels (Fig. 3) . This is in line with previous studies, which have proven that expression analyses in LCL cells are informative in neurological and neuropsychiatric traits [15] [16] [17] . No significant association was detected in fibroblasts or primary T cells. The eQTL analysis suggested that rs1835740 is a cis regulator of MTDH in LCLs. The location of the associating sequence variant, rs1835740, between two genes involved in glutamate homeostasis, PGCP and MTDH, suggests that this region contains elements that could regulate either or both of these flanking genes; the eQTL analysis pointed to the latter. Although MTDH has mainly been studied in relation to carcinogenesis 18 , previous studies in cultured astrocytes have shown that MTDH downregulates SLC1A2 (also known as EAAT2 and GLT-1) [18] [19] [20] [21] [22] , the gene encoding the major glutamate transporter in the brain. Furthermore, knock-out mice lacking the EAAT2 protein from their brains have been shown to suffer from lethal spontaneous epileptic seizures 23 . Despite the limitations in extrapolating eQTL findings from LCL cells directly to brain tissue, these data suggest a plausible link between the identified variant and glutamate regulation. This is a tempting hypothesis, as this neurotransmitter has long been suspected to play a key role in migraine pathophysiology 24 .
Although the evidence provided here is indirect, accumulation of excess glutamate in the synaptic cleft through downregulation of EAAT2 or an increase in PGCP activity (or both) would provide a putative mechanism for the occurrence of migraine attacks. It is reasonable to speculate that this accumulation can increase susceptibility to migraine through increased sensitivity to cortical spreading depression, the likely mechanism for the migraine aura 9, 10 , as well as through glutamate involvement in central sensitization, which has been postulated to be the underlying mechanism of allodynia during a migraine attack 25 .
Neither this study nor our previous study 3 yielded evidence for association of ion channel genes to common forms of migraine. Thus, even if the contribution of ion channel genes is well established in Mendelian forms of paroxysmal neurological disorders, such as familial hemiplegic migraine (FHM) [26] [27] [28] [29] , their direct role in more common forms of paroxysmal neurological disorders remains open. Interestingly, previous studies suggested that the imbalance of glutamate release and clearance is a key component of the pathogenesis of FHM; the underlying mutation in FHM lies in CACNA1A, ATP1A2 or SCN1A 30, 31 . The results of the present study support the hypothesis that complementary pathways such as the glutamate system may tie the Mendelian channelopathies with the pathogenetic mechanisms of more common forms of episodic neurological disorders, such as migraine. Alterations in the functionally related EAAT1 transporter have been identified in other episodic phenotypes (such as episodic ataxia 6 (ref. 32 ) and a phenotype with episodic ataxia, hemiplegia and seizures 33 ), providing an example of the link between EAAT transporters and episodic disorders. Future studies should be conducted to specifically test this hypothesis.
In summary, to our knowledge, we have identified the first robust genetic association to migraine. As our cases were mainly selected from specialized headache clinics, subsequent studies are needed to establish the contribution of rs1835740 in population-based migraine cohorts. These populationbased cohorts may represent a different severity spectrum and possibly also a somewhat different underlying combination of genetic susceptibility variants. The effect of rs1835740 is stronger in individuals with migraine with aura than in those with migraine without aura, but further studies are needed to confirm the role of the variant in different migraine subgroups. This variant explains only a small fraction of the overall genetic variance in migraine, and future GWAS, perhaps with different ascertainment schemes, will likely identify additional loci explaining more of the genetic variance.
METhods
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Accession codes. Migraine, OMIM 157300.
Note: Supplementary information is available on the Nature Genetics website. , the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII) and the Municipality of Rotterdam. We wish to thank S. Hunt, R. Gwillian, P. Whittaker, S. Potter and A. Tashakkori-Ghanbarian, as well as P. Marin-Garcia, for their invaluable help with this study. Finally, we wish to collectively thank everyone who has contributed to the collection, genotyping and analysis of the individual cohorts.
ACKNOWLEDGMENTS

AUTHOR CONTRIBUTIONS
All authors contributed to the current version of the paper.
